Related Experiment Video
Updated: Oct 16, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
Published on: March 17, 2014
Pseudomonas spp. complications in patients with HIV disease: an eight-year clinical and microbiological survey
R Manfredi1, A Nanetti, M Ferri
1Dipartimento di Medicina Clinica Specialistica e Sperimentale, Universitai degli Studi di Bologna, Italy.
Abstract:
Two hundred and twenty-four episodes of Pseudomonas spp. complications that occurred in 179 consecutive patients with HIV infection were retrospectively reviewed. Pseudomonas spp. organisms were responsible for 11.6% of 1933 episodes of non-mycobacterial bacterial diseases (5.4% of 1072 episodes of sepsis), observed over an 8-year period; 20.7% of patients experienced disease relapses (45 episodes). These complications mostly involved lower airways (66 cases), urinary tract (53 episodes), and blood (34 cases), with Pseudomonas aeruginosa isolated in 161 episodes, and other Pseudomonas spp. in the remaining 63 cases. An advanced HIV disease was frequently present (as expressed by a prior diagnosis of AIDS, a low CD4+ lymphocyte count, and leukopenia-neutropenia). Indwelling intravascular and urinary catheters were often associated with bacteremia and urinary tract involvement, respectively. More than 60% of patients were given antibiotics and/or cotrimoxazole in the month preceding the onset of Pseudomonas spp. disease. Bacterial strains isolated from our HIV-infected patients showed a favorable sensitivity to piperacillin, ceftazidime, imipenem, amikacin, tobramycin, and ciprofloxacin. An adequate antimicrobial treatment led to clinical and microbiological cure in 73.2% of patients at the first episode, and in 22.3% more subjects after one or more relapses. A lethal outcome occurred in only eight patients of 179 (4.5%), suffering from a far advanced HIV disease; P. aeruginosa infection directly contributed to death in four cases (sepsis, and/or pneumonia). Nosocomial disease occurred in 46.4% of the 224 episodes, and was significantly related to a previous diagnosis of AIDS, concurrent neutropenia, the occurrence of sepsis or urinary tract infection, disease relapses, the involvement of non-aeruginosa Pseudomonas spp., and a lethal outcome, compared with community-acquired infection. Our experience (the largest reported to date) confirms that Pseudomonas spp. (including non-aeruginosa Pseudomonas spp. organisms) is responsible for remarkable morbidity and mortality among patients with HIV infection, and may pose relevant problems to clinicians and microbiologists involved in the care of HIV-infected patients.
Insights
Pseudomonas species cause significant complications in HIV patients, particularly those with advanced disease. Early treatment improves outcomes, but relapses and nosocomial infections remain challenges.
Area of Science:
- Infectious Diseases
- Microbiology
- HIV/AIDS Research
Background:
- Pseudomonas species are opportunistic pathogens causing serious infections in immunocompromised individuals.
- Patients with Human Immunodeficiency Virus (HIV) infection are at increased risk for bacterial complications, including those caused by Pseudomonas.
Purpose of the Study:
- To retrospectively review Pseudomonas species complications in HIV-infected patients.
- To analyze the clinical characteristics, treatment outcomes, and mortality associated with Pseudomonas infections in this population.
Main Methods:
- Retrospective review of 224 episodes of Pseudomonas complications in 179 HIV-infected patients over an 8-year period.
- Analysis of patient demographics, clinical presentation, microbiological data, treatment regimens, and outcomes.
- Comparison of nosocomial versus community-acquired Pseudomonas infections.
Main Results:
- Pseudomonas species accounted for 11.6% of non-mycobacterial bacterial diseases and 5.4% of sepsis episodes in HIV patients.
- Lower airways, urinary tract, and bloodstream infections were most common.
- Patients often had advanced HIV disease (low CD4+ counts, neutropenia) and frequent relapses (20.7%).
- Favorable antibiotic sensitivities were observed for piperacillin, ceftazidime, imipenem, amikacin, tobramycin, and ciprofloxacin.
- Clinical cure rates were 73.2% for the first episode and an additional 22.3% after relapses.
- Mortality was 4.5%, primarily in patients with advanced HIV disease.
- Nosocomial infections were associated with poorer outcomes.
Conclusions:
- Pseudomonas species, including non-aeruginosa strains, contribute significantly to morbidity and mortality in HIV-infected patients.
- Advanced HIV disease and indwelling catheters are risk factors.
- Prompt and appropriate antimicrobial therapy is crucial for successful treatment and reducing mortality.
- Nosocomial Pseudomonas infections present a substantial clinical challenge in this patient group.
Related Concept Videos
Cryptococcal Meningitis
Pneumonia III: Complications and Assessment
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia II: Pathophysiology

